068270.KS
Celltrion, Inc.
KSEKRWEQUITY
Healthcare
DELAYED
Last price
192,300.00
▼ 1,800.00 (0.93%)
MARKET · —
Price
Open
192,100.00
Prev close
194,100.00
Day high
193,100.00
Day low
187,600.00
Volume
354.96K
Market cap
$44.10T
P/E (TTM)
—
52W range
158,500.00 – 239,047.62
Trailing performance
Returnvs SPY
1W
-4.80%
-3.4%
1M
+13.05%
+9.3%
3M
+12.55%
+9.5%
6M
-15.34%
-26.4%
YTD
+11.56%
-0.7%
1Y
+13.12%
-6.9%
3Y
+50.40%
-23.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$44.10T
Enterprise value$46.75T
Revenue (TTM)$4.47T
Gross profit$2.71T
EBITDA$1.63T
Net income$1.27T
EPS (TTM)—
Free cash flow$20.78B
Total cash$1.42T
Total debt$3.87T
Book value / share—
Shares outstanding229.33M
Float152.20M
Short % of float—
Dividend yield0.37%
Beta (5Y)0.32
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio0.85
Price / sales—
Price / book—
EV / revenue10.47
EV / EBITDA28.68
Gross margin60.69%
Operating margin28.11%
Profit margin28.38%
Return on equity7.26%
Return on assets3.79%
Debt / equity21.70
Current ratio1.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $4.16T | $3.56T | $1.87T | $2.28T |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.03T | $422.69B | $563.27B | $533.17B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.03T | $422.69B | $563.27B | $533.17B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1,450.51 | 1,609.00 | +10.9% |
| Mar 2026 | 987.15 | 1,500.95 | +52.1% |
| Dec 2025 | 1,425.31 | 2,283.81 | +60.2% |
| Sep 2025 | 1,070.53 | 1,436.19 | +34.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1,622.68 | 3 | $1.47T | +43.1% |
| Next quarter | 1,708.67 | 3 | $1.62T | +21.8% |
| Current year | 6,571.24 | 20 | $5.48T | +31.7% |
| Next year | 7,545.61 | 23 | $6.29T | +14.8% |
Analyst targets & ownership
Mean target$266,031.66
High target$330,000.00
Low target$200,000.00
Implied upside38.34%
Analyst count23
ConsensusBUY
Strong buy / Buy8 / 13
Hold2
Sell / Strong sell0 / 0
Held by insiders36.17%
Held by institutions20.39%
Institutions holding250
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
83.07M
Total on file
Moving averages & technicals
SMA 10
199,180.00
-3.45% from price
SMA 20
191,775.00
+0.27% from price
SMA 50
180,714.00
+6.41% from price
SMA 100
183,460.14
+4.82% from price
SMA 200
187,517.21
+2.55% from price
EMA 12
194,845.65
-1.31% from price
EMA 26
189,965.36
+1.23% from price
EMA 50
185,906.07
+3.44% from price
RSI (14)
53.0
Neutral
MACD (12,26,9)
4,880.29
Hist -739.99
ATR (14)
7,117.86
3.70% of price
Realised vol 30D
33.5%
Annualised
Bollinger upper
210,200.84
20, 2σ
Bollinger lower
173,349.16
20, 2σ
50 / 200 cross
Death
180,714.00 vs 187,517.21
Trend bias
Above 200
+2.55%
Risk profile
Beta vs SPY
0.01
Less volatile than market
Correlation to SPY
0.00
Largely independent
Realised vol 30D
33.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-32.6%
Peak to trough
Max drawdown 5Y
-52.5%
Peak to trough
ATR 14
7,117.86
3.70% of price
Beta (reported)
0.32
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
The CMBS Maturity Wall Hides a Sharp Refinancing Reset
CRE Daily · 3m ago
JPMREIT’s First Office Buy Lags Its Industrial Portfolio
CRE Daily · 8m ago
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
AFP · 12m ago
Invesco Cuts Fees 20% to Stem Property Fund Redemptions
CRE Daily · 14m ago
EOG Resources (EOG) Stock Still Looks A Bargain On Earnings Yet Fully Priced On Returns
Simply Wall St. · 15m ago
Artemis Gold (TSXV:ARTG) Stock Still Looks Reasonable Despite Its 7x Run
Simply Wall St. · 15m ago
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Simply Wall St. · 15m ago
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns
Simply Wall St. · 15m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.